China’s National Medical Products Administration (NMPA) has approved Zeiss Medical Technology’s retinal imaging system, the ZEISS CLARUS 700, with fluorescein angiography (FA).
It will aid eye care specialists in China with diagnostic tools to preserve patient vision.
Go deeper with GlobalData
The ultra-widefield FA serves as a tool for evaluating nonperfused retinal regions.
Offering high-resolution and True Color images, the fundus imaging camera is equipped with features such as PrecisionFocus for rapid view of details, QuickCompare for comparing pathology changes found in previous visits of the patient, and AutoBright, which streamlines the imaging process.
ZEISS CLARUS 700 claims to capture 133° in one image and up to 267° with several captures. It also includes live infrared imaging offerings.
The images produced by the platform closely mimic the actual colouration of the fundus as seen in direct clinical observation.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataUltra-widefield FA can identify conditions such as diabetic retinopathy by visualising the peripheral retina.
This is essential for evaluating neovascularisations, vascular leakage, and other microvascular abnormalities.
The high resolution and widefield imaging of the ZEISS CLARUS 700 enable the capture of minute details from the ONH to the periphery, even in the early phase of diseases.
The device also features technology that utilises patented technology to maximise workflow efficiency and reduce the time patients spend in the chair. These features are designed to allow specialists to focus more on patient care.
Various new features have been introduced by the device that enable clinicians to focus on their patients.
These features, leveraging algorithms via patented technology, will aid in reducing the chair time.
ZEISS medical technology chronic disease management head Anuj Kalra said: “By seamlessly integrating ultra-widefield FA imaging with true-colour reproduction, this system delivers unprecedented clarity for comprehensive visualisation from the macular region to the extreme retinal periphery, enhancing efficiency and supporting precise decision-making within the ZEISS Retina Workflow.”
In 2023, Zeiss Medical Technology entered a long-term strategic partnership with Boehringer Ingelheim to develop predictive analytics for eye conditions.
